To be fair, most of the "new drug development" that is needed is not what is most profitable. I'm not sure if 30 versions of ED medicine really translate to a better social outcome for us all, really.
Similarly, there hasn't been a lot of new development from Mylar on the epi-pen that connects it to its recent 67% price hike, has there?
I'm not naive enough to think it immoral that drug companies investing in R&D should be fairly compensated, however being willfully ignorant of what is happening in Pharma R&D in the US doesn't really help matters.
The simple reality is that taxpayers fund a good deal of pharmaceutical R&D, drug prices have little to no relationship to their actual cost, and these companies do a very good job of exploiting loopholes to pay as little tax back into the system as possible. There are a lot of issues there, but at the end of the day, the only reason drug prices are so high in the US is that consumers aren't protected from hikes in the same way they are by other countries that view affordable health care as a part of their mandate. I think you'd probably get a lot more benefit overall in reverting the US to a model similar to the rest of the world, rather than forcing the rest of the world to abandon their previous positions in Trump-like bluster. The US isn't as isolated as some of its citizens think it is.